EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions

Archana Mishra iD, Rituparna Maiti iD, Prafull Mohan iD, Pooja Gupta iD

European Journal of Haematology · 2024-02 · 112 (2) · 211-222

DOI: 10.1111/ejh.14101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 13.09.2023. Verfasst von Archana Mishra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric Antigen Receptor T‐cell (CAR‐T cell) therapy has emerged as a groundbreaking immunotherapeutic approach for treating various hematological malignancies. CAR‐T cells are engineered to express synthetic receptors that target specific antigens on cancer cells, leading to their eradication. While the therapy has shown remarkable efficacy, a significant challenge that has been observed in 30%–70% of patients showing recurrent disease is antigen loss or downregulation. We searched PubMed/MEDLINE, EMBASE, and Google scholar for articles on antigen loss/escape following Chimeric antigen receptor T‐cell therapy in malignancies. Antigen loss refers to the loss or reduction in the expression of the target antigen on cancer cells, rendering CAR‐T cells ineffective. This phenomenon poses a significant clinical concern, as it can lead to disease relapse and limited treatment options. This review explores the mechanisms underlying antigen loss following CAR‐T cell therapy, its implications on treatment outcomes, and potential strategies to overcome the problem.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHumansReceptors, Antigen, T-CellT-LymphocytesNeoplasm Recurrence, LocalImmunotherapy, AdoptiveCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CAR-Tantigen lossdual targeted CARnovel CAR designs

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
  • Clinical Pharmacologist, Armed Forces Medical Services, Guwahati, India.
  • Department of Pharmacology, All India Institute of Medical Sciences, Delhi, India.

ORCID-Profile: Archana Mishra, Rituparna Maiti, Prafull Mohan, Pooja Gupta

Zitieren

APA

Mishra, A., Maiti, R., Mohan, P., & Gupta, P. (2024). Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions. European Journal of Haematology, 112(2), 211-222. https://doi.org/10.1111/ejh.14101

Vancouver

Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions. European Journal of Haematology. 2024;112(2):211-222. doi:10.1111/ejh.14101

BibTeX
@article{Mishra2024,
  author = {Mishra, Archana and Maiti, Rituparna and Mohan, Prafull and Gupta, Pooja},
  title = {Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {112},
  number = {2},
  pages = {211--222},
  doi = {10.1111/ejh.14101}
}
Kostenlos starten →